Detailed Information
Cited 4 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial
- Authors
- Rugo, HS[Rugo, Hope S.]; Oliveira, M[Oliveira, Mafalda]; Howell, SJ[Howell, Sacha Jon]; Dalenc, F[Dalenc, Florence]; Cortes, J[Cortes, Javier]; Gomez, HL[Gomez, Henry Leonidas]; Hu, XC[Hu, Xichun]; Iwata, H[Iwata, Hiroji]; Jhaveri, KL[Jhaveri, Komal L.]; Loibl, S[Loibl, Sibylle]; Murillo, SM[Murillo, Serafin Morales]; Okera, M[Okera, Meena]; Park, YH[Park, Yeon Hee]; Sohn, J[Sohn, Joohyuk]; Zhukova, L[Zhukova, Lyudmila]; Logan, J[Logan, Jill]; Twomey, K[Twomey, Ken]; Khatun, M[Khatun, Mahmuda]; D'Cruz, CM[D'Cruz, Celina M.]; Turner, NC[Turner, Nicholas C.]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.